Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy

Urologia Internationalis

Volumn 88, Issue 3, 2012, Pages 263-270

  Sejima, Takehiro ^a   Morizane, Shuichi ^a   Hinata, Nobuyuki ^a   Yao, Akihisa ^a   Isoyama, Tadahiro ^a   Saito, Motoaki ^a   Takenaka, Atsushi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Nephrectomy; Prognostic factors; Renal cell carcinoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84860322150     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000334453     Document Type: Article

References (27)

1. Nagata S, Golstein P: The Fas death factor. Science 1995; 267: 1449-1456.
2. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178. (Pubitemid 24006113)
3. Cohen JJ, Duke RC, Fadok VA, Sellins KS: Apoptosis and programmed cell death in immunity. Annu Rev Immunol 1992; 10: 267-293.
4. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652. (Pubitemid 24270685)
5. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999; 20: 158-160. (Pubitemid 29172275)
6. Real LM, Jimenez P, Kirkin A, Serrano A, García A, Cantón J, Zeuthen J, Garrido F, Ruiz-Cabello F: Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 2001; 49: 621-628. (Pubitemid 33783078)
7. Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ: Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 2009; 69: 6615-6623.
8. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
9. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336. (Pubitemid 120029101)
10. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA: bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993; 53: 3321-3326. (Pubitemid 23223304)
11. Sejima T, Miyagawa I: Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int J Urol 2006; 13: 257-264.
12. Macher-Goeppinger S, Bermejo JL, Wagener N, Hohenfellner M, Haferkamp A, Schirmacher P, Roth W: Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett 2011; 301: 203-211.
13. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kakizoe T, Kawabe K: Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol 1997; 27: 384-388. (Pubitemid 127519259)
14. Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T, Takahashi K, Tomita Y: Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 2006; 95: 1244-1249. (Pubitemid 44658490)
15. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME: CD95 promotes tumour growth. Nature 2010; 465: 492-496.
16. Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E, Ste Marie R, Wang TC, Lyle S, Kurt-Jones E, Houghton J: Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology 2009; 137: 934-944.
17. Ryan AE, Shanahan F, O'Connell J, Houston AM: Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006; 5: 246-249. (Pubitemid 43213492)
18. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675. (Pubitemid 28267863)
19. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012. (Pubitemid 27138590)
20. Ryan AE, Shanahan F, O'Connell J, Houston AM: Addressing the 'Fas counterattack' controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005; 65: 9817-9823. (Pubitemid 41541459)
21. Igney FH, Krammer PH: Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005; 54: 1127-1136. (Pubitemid 41396816)
22. Paraf F, Gogusev J, Chrétien Y, Droz D: Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995; 177: 247-252.
23. Zhang X, Takenaka I: Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology 2000; 56: 510-515. (Pubitemid 30658199)
24. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S: Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002; 59: 615-620. (Pubitemid 34249907)
25. Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis C, Dimopoulos MA: Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int J Urol 2005; 12: 563-569. (Pubitemid 41097834)
26. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF: Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-136. (Pubitemid 46158371)
27. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-628. (Pubitemid 40038739)